On 18 November 2016, orphan designation (EU/3/16/1791) was granted by the European Commission to Dr Ulrich Granzer, Germany, for a vaccine consisting of 5 survivin peptides with different human leukocyte antigen restrictions (also known as DPX-Survivac) for the treatment of ovarian cancer.
The sponsorship was transferred to FGK Representative Service GmbH, Germany, in June 2020.
vaccine consisting of 5 survivin peptides with different human leukocyte antigen restrictions
|Disease / condition||
Treatment of ovarian cancer
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.